Company: ABUS
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001447028-25-000099
Chunk: 15

Company: Arbutus Biopharma Corp
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
553)Net change in operating items:Accounts receivable1,227 (363)Prepaid expenses and other assets413 (156)Accounts payable and accrued liabilities4,545 (2,024)Change in deferred license revenue(812)(244)Other liabilities(104)(72)Net cash used in operating activities(13,391)(19,295)INVESTING ACTIVITIESPurchase of investments in marketable securities(34,716)(25,397)Disposition of investments in marketable securities46,065 37,186 Acquisition of property and equipment— (95)Net cash provided by investing activities11,349 11,694 FINANCING ACTIVITIESIssuance of common shares pursuant to the Open Market Sale Agreement— 21,765 Issuance of common shares pursuant to exercise of stock options2,653 2,454 Issuance of common shares pursuant to ESPP131 211 Net cash provided by financing activities2,784 24,430 Effect of foreign exchange rate changes on cash and cash equivalents4 (13)Increase in cash and cash equivalents746 16,816 Cash and cash equivalents, beginning of period36,330 26,285 Cash and cash equivalents, end of period$37,076 $43,101 

See accompanying notes to the condensed consolidated financial statements.

5

ARBUTUS BIOPHARMA CORPORATION

Notes to Condensed Consolidated Financial Statements

(Tabular amounts in thousands of U.S. Dollars, except share and per share amounts) 

1.    Nature of business and future operations

Description of the BusinessArbutus Biopharma Corporation (“Arbutus” or the “Company”) is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is currently developing imdusiran (AB-729), its proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The Company continues to protect and defend its intellectual property, which is the subject of its ongoing lawsuits against Moderna Therapeutics, Inc. (Moderna) and against Pfizer Inc. and BioNTech SE (collectively, Pfizer/BioNTech) for their use of the Company’s patented lipid nanoparticle (LNP) delivery technology in their COVID-19 messenger rib